Eight weekly infusions of rituximab (R) for relapsed patients (pts) with indolent B-cell lymphoma mostly pretreated with R: A Japanese multicenter phase II study

Authors :: Kuniaki Itoh
Mitsutoshi Kurosawa
Kensei Tobinai
K. Murayama
Takashi Watanabe
Tadahiko Igarashi
Hirokazu Nagai
Source :: Journal of Clinical Oncology. 28:e18510-e18510
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: e18510 Background: To evaluate the efficacy and safety of R × 8 dosing monotherapy in pts with relapsed or refractory indolent B-cell NHL with pharmacokinetic (PK) assessment. Methods: In a multi-c...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
medicine.disease
Surgery
Refractory
Pharmacokinetics
Internal medicine
Medicine
Rituximab
Dosing
business
B-cell lymphoma
medicine.drug

Full Text Access

Tools